Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of BioNtech Are Jumping Tuesday

By Jim Halley – Aug 17, 2021 at 1:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The news that the Biden Administration would push for booster shots for COVID-19 vaccinations helps the biotech, which paired with Pfizer on a vaccine.

What happened

BioNTech (BNTX 1.31%) saw its shares rise more than 8% in early trading on Tuesday. The biotech's stock closed at $343.10 on Monday, opened at $322 on Tuesday, then bounced back to a high of $366 by early morning. It was another wild ride for the company's investors, who have seen the stock go as high as $464 and as low as $54.10 over the past 52 weeks.

A man getting a vaccine from a female health worker.

Image source: Getty Images.

So what

There are two factors helping to drive the stock's shares.

On Monday, the company and Pfizer released phase 1 data saying that its Pfizer-BioNtech COVID vaccine (BNT162b2), when given as a booster shot, appeared to be safe and effective in developing antibodies to fight the beta and delta variants, as well as the original COVID strain. It added that phase 3 data was expected soon. The shot was given to test subjects eight to nine months after they had received their second dose of the same vaccine. The phase 1 results showed that a third dose brought a higher rate of neutralizing antibodies against the regular strain of COVID-19 as well as against the beta and delta variants.

The other bit of good news is that the Biden administration will push for COVID booster shots. According to a New York Times article published Monday, the planned announcement will apply only to those who have had the Moderna or Pfizer vaccines.

Now what

Investors had cooled to what they might think is a too-high valuation for BioNTech, but the company's P/E ratio has fallen from above 600 to a reasonable 18.78.

Sales from its COVID vaccine have helped drive profits, but when the company's second-quarter numbers fell short of expectations, the stock dropped. Looking at the big picture, though, the company reported $6.4 billion in revenue, up 159% year over year, and net income of $3.6 billion, up 147.3% compared to the same period in 2020.

It's true that the company's near-term future is intertwined with the need for its vaccine, so there's plenty of risk, but it appears for now that the profits are likely to roll in for a while.

Jim Halley owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$163.61 (1.31%) $2.12
Pfizer Stock Quote
Pfizer
PFE
$49.49 (-0.16%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.